Close Menu

NEW YORK (GenomeWeb) – In an update to its 2018 breast cancer guidelines, the National Comprehensive Cancer Network (NCCN) has made changes in how it endorses the use of, or how it describes, various genetic tests. One major change involved the categorization of Genomic Health's Oncotype DX Breast Recurrence Score as a "preferred" test for chemotherapy treatment decision-making in patients with node-negative early-stage breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.